Jackson Creek Investment Advisors LLC bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,290 shares of the company’s stock, valued at approximately $1,286,000.
Several other hedge funds have also recently made changes to their positions in the business. AQR Capital Management LLC raised its position in shares of Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after buying an additional 404,226 shares in the last quarter. Wasatch Advisors LP raised its position in Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after purchasing an additional 116,354 shares during the period. Invesco Ltd. raised its position in Medpace by 18.9% in the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after purchasing an additional 85,517 shares during the period. UBS Group AG raised its position in Medpace by 32.8% in the 4th quarter. UBS Group AG now owns 328,879 shares of the company’s stock worth $184,715,000 after purchasing an additional 81,250 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its position in Medpace by 205.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after purchasing an additional 211,411 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.
Medpace Price Performance
Shares of MEDP stock opened at $428.00 on Thursday. The company has a market capitalization of $12.22 billion, a P/E ratio of 26.90, a P/E/G ratio of 2.18 and a beta of 1.19. The company’s 50-day simple moving average is $457.76 and its two-hundred day simple moving average is $515.44. Medpace Holdings, Inc. has a one year low of $291.28 and a one year high of $628.92.
Wall Street Analysts Forecast Growth
A number of analysts recently weighed in on MEDP shares. BMO Capital Markets reduced their price objective on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research report on Friday, April 24th. Leerink Partners reduced their price objective on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 11th. Royal Bank Of Canada reduced their price objective on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Barclays reduced their price objective on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research report on Friday, April 24th. Finally, Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Four investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Medpace currently has an average rating of “Hold” and an average target price of $467.08.
Check Out Our Latest Stock Analysis on Medpace
Trending Headlines about Medpace
Here are the key news stories impacting Medpace this week:
- Negative Sentiment: Several firms, including Rosen, Glancy Prongay, Levi & Korsinsky, Schall, Pomerantz, and others, issued reminders about the ongoing class action and the June 8 lead-plaintiff deadline, keeping legal overhang front and center for shareholders. Article Title
- Negative Sentiment: One lawsuit notice specifically highlights allegations that Medpace misled investors about cancellation rates and book-to-bill ratio, and references a prior 16% stock drop tied to those disclosures, reinforcing fears of further liability or reputational damage. Article Title
- Neutral Sentiment: Zacks published a comparison of Medpace versus Labcorp on valuation, which may influence investor sentiment only modestly and does not appear to be a major stock-moving catalyst. Article Title
Insider Buying and Selling
In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the company’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the transaction, the president directly owned 15,000 shares in the company, valued at $6,829,500. This represents a 67.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 20.50% of the stock is owned by corporate insiders.
Medpace Company Profile
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Featured Stories
- Five stocks we like better than Medpace
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
- Keysight: The AI and Defense Stock Seeing Big Price Target Boosts
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
-plc-logo-1200x675.png){kind=logo}
